参松养心胶囊联合华法林治疗心房颤动的临床研究

目的观察参松养心胶囊联合华法林治疗心房颤动的临床疗效。方法选取2015年1月—2015年12月柞水县人民医院心房颤动患者106例,随机分为治疗组和对照组,每组各53例。对照组口服华法林钠片,初始剂量1.5 mg/d,3 d后,根据国际标准化比值(INR)检测结果调整华法林用量,确保INR处于2.0~3.0;治疗组在对照组基础上口服参松养心胶囊,3粒/次,3次/d。两组患者均治疗12周。观察两组的临床疗效,比较两组房颤发作、心率、INR和高敏C反应蛋白(hs-CRP)的变化。结果治疗后,对照组和治疗组的总有效率分别为69.81%、88.68%,两组比较差异有统计学意义(P0.05)。治疗后,两组房颤发作持续时间和发作频率均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的下降程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组静息心率和运动心率均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的下降程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗4周后,两组INR显著上升,而hs-CRP水平显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的下降程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论参松养心胶囊联合华法林治疗心房颤动具有较好的临床疗效,可明显改善临床症状,降低hs-CRP的表达,具有一定的临床应用推广价值。

Clinical observation of Shensong Yangxin Capsules combined with warfarin in treatement of atrial fibrillation

Objective To observe the clinical effect of Shensong Yangxin Capsules combined with warfarin in treatement of atrial fibrillation. Methods Patients (106 cases) with atrial fibrillation in Zhashui County People''s Hospital from January 2015 to December 2015 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Warfarin Sodium Tablets, 1.5 mg/d, and according to the INR results to adjust the dosage of warfarin after 3 d, ensure that the INR is 2.0-3.0. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the changes of atrial fibrillation attack, heart rate, INR, and hs-CRP in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there was difference between two groups (P<0.05). After treatment, the duration and frequency of atrial fibrillation attack in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, resting heart rate and exercise heart rate in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 4 weeks, the INR in two groups were significantly increased, but the hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shensong Yangxin Capsules combined with warfarin has clinical curative effect in treatement of atrial fibrillation, and can significantly improve clinical symptoms, decrease hs-CRP level, which has a certain clinical application value.